Medical Devices & Tech

Vessix Vascular (Formerly Minnow Medical)

26052 Merit Circle, Suite 106
Laguna Hills, CA 92653 USA
Phone
Fax
Click for website

Research Sector Medical Devices & Tech

Summary Description Catheter-based Energy Treatment for Peripheral Artery Disease, including in-stent restenosis and DVT.

Management Raymond W. Cohen, Chief Executive Officer Prabodh Mathur, Chief Product Development Officer Sharon Riddle, Vice President of Market Development; Mike Handley, VP, Clinical and Regulatory Affairs Dan Dearen, Chief Financial Officer; Olav Bergheim, Chairman

Click here for Financial Data
Keywords: cardiovascular disease, artery disease, catheter technology, peripheral artery disease, in-stent restenosis, DVT

Comment


Updated: Aug. 22, 2013


Description

Vessix Vascular, Inc. continues to expand the endovascular clinical applications for its patented low-pressure percutaneous transluminal angioplasty catheter mounted with RF electrodes. The Company......view more

Products / Services

Through collaboration with leading physicians, researchers and scientists, Minnow Medical has developed its initial product, the ZCath Peripheral Vascular System. The ZCath combines a patented low-......view more

Technology / Differentiation

Established peripheral artery procedures utilize a wide range of technologies from surgical by-pass to endovascular treatments such as angioplasty, stenting, laser, and atherectomy therapy. These ther...view more

Market / Customers

In-Stent Restenosis (ISR) in the peripheral arteries is Minnows primary target market. Historically, arterial disease in the superficial femoral artery (SFA) has been treated with bypass surger......view more


Competitors / Substitutes / Alternatives

Current catheter-based treatments for artery disease include; plain old balloon angioplasty, laser, cryoplasty and atherectomy....view more

Strategy

Establish clinical efficacy for various clinical indications and partner with large established players to license and distribute our products....view more

Revenue / Funding

We are seeking $7 to $10 million in new capital to complete our European study for ISR which is scheduled to begin in late Q1 2011 and to conduct a clinical study in the U.S. Proceeds from the financi...view more

Status

Minnow has already treated over 80 patients in Europe, has a CE Mark for its ZCath System and a 510(k) pending with the FDA for its initial indication. The Company is planning a new study to treat pat...view more

RELATED COMPANIES



0000-00-00-9831